[ad_1]
U.S. Capital Wealth Advisors LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,420 shares of the company’s stock after purchasing an additional 2,532 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,804,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in MRK. McLean Asset Management Corp lifted its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after buying an additional 125 shares in the last quarter. Foundation Wealth Management LLC PA raised its holdings in shares of Merck & Co., Inc. by 2.4% during the 1st quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock worth $481,000 after acquiring an additional 127 shares in the last quarter. Saiph Capital LLC boosted its position in shares of Merck & Co., Inc. by 3.7% during the 1st quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after acquiring an additional 128 shares during the last quarter. Physician Wealth Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 2.9% in the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock valued at $363,000 after purchasing an additional 128 shares in the last quarter. Finally, N.E.W. Advisory Services LLC increased its position in Merck & Co., Inc. by 2.6% in the first quarter. N.E.W. Advisory Services LLC now owns 5,197 shares of the company’s stock worth $466,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.
Analyst Upgrades and Downgrades
MRK has been the subject of several research reports. Wells Fargo & Company lowered their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Finally, Morgan Stanley dropped their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $106.41.
Check Out Our Latest Stock Analysis on Merck & Co., Inc.
Merck & Co., Inc. Stock Performance
Shares of NYSE:MRK opened at $79.89 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $116.26. The company has a market capitalization of $199.54 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 0.83 and a beta of 0.37. The firm’s 50-day moving average is $82.69 and its 200 day moving average is $82.23.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.
Merck & Co., Inc. Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 4.1%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.92%.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
See Also
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link